We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+54.5%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$583M
AUM Growth
+$84.1M
Cap. Flow
-$23.8M
Cap. Flow %
-4.08%
Top 10 Hldgs %
45.64%
Holding
119
New
32
Increased
28
Reduced
17
Closed
42

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$25.6M
2
ABVX
Abivax
ABVX
+$24.6M
3
TWST icon
Twist Bioscience
TWST
+$16.2M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$12.6M
5
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.9M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$63.7M
2
DNLI icon
Denali Therapeutics
DNLI
+$22.2M
3
IMVT icon
Immunovant
IMVT
+$21.1M
4
QURE icon
uniQure
QURE
+$18.5M
5
WVE icon
Wave Life Sciences
WVE
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$11.9B
$52.8M 9.06%
391,783
+225,510
+136% +$24.6M
SRRK icon
2
Scholar Rock
SRRK
$6.33B
$39.1M 6.7%
886,893
+160,689
+22% +$6.03M
CNTA
3
DELISTED
Centessa Pharmaceuticals
CNTA
$28.9M 4.95%
1,154,114
+498,729
+76% +$12.6M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$2.02B
$28.1M 4.83%
1,339,379
-26,826
-2% -$468K
GPCR icon
5
Structure Therapeutics
GPCR
$3.45B
$24.4M 4.19%
351,073
+221,738
+171% +$9.05M
ACLX
6
DELISTED
Arcellx
ACLX
$21.7M 3.72%
332,860
+321,484
+2,826% +$25.6M
ROIV icon
7
Roivant Sciences
ROIV
$24.8B
$21M 3.6%
966,698
-3,230,489
-77% -$63.7M
TERN
8
DELISTED
Terns Pharmaceuticals
TERN
$17.3M 2.97%
429,198
+339,581
+379% +$7.85M
TWST icon
9
Twist Bioscience
TWST
$5.84B
$16.4M 2.82%
+518,355
New +$16.2M
IMVT icon
10
Immunovant
IMVT
$8.27B
$16.4M 2.81%
644,959
-944,621
-59% -$21.1M
DYN icon
11
Dyne Therapeutics
DYN
$3.92B
$16.3M 2.8%
835,200
+360,588
+76% +$6.83M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.6B
$15.6M 2.68%
348,605
+156,310
+81% +$6.56M
SRZN icon
13
Surrozen
SRZN
$255M
$12.7M 2.17%
619,766
-93,697
-13% -$1.52M
CELC icon
14
Celcuity
CELC
$4.31B
$11.8M 2.02%
118,333
-18,377
-13% -$1.51M
MLYS icon
15
Mineralys Therapeutics
MLYS
$2.39B
$10.5M 1.8%
290,049
+131,937
+83% +$5.29M
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$12.8B
$10.3M 1.77%
17,736
+9,529
+116% +$4.87M
ADPT icon
17
Adaptive Biotechnologies
ADPT
$3.67B
$9.85M 1.69%
+606,825
New +$9.9M
PALI icon
18
Palisade Bio
PALI
$342M
$9.85M 1.69%
+4,192,375
New +$8.06M
CYTK icon
19
Cytokinetics
CYTK
$10.9B
$9.34M 1.6%
+146,978
New +$9.14M
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.28B
$8.96M 1.54%
+360,876
New +$7.24M
DRUG
21
Bright Minds Biosciences
DRUG
$747M
$7.6M 1.3%
+97,340
New +$6.51M
NKTR icon
22
Nektar Therapeutics
NKTR
$2.31B
$7.54M 1.29%
178,274
+125,073
+235% +$7M
JNJ icon
23
Johnson & Johnson
JNJ
$609B
$7.24M 1.24%
+35,000
New +$6.92M
DNLI icon
24
Denali Therapeutics
DNLI
$3.7B
$6.92M 1.19%
419,058
-1,315,601
-76% -$22.2M
AMLX icon
25
Amylyx Pharmaceuticals
AMLX
$1.97B
$6.83M 1.17%
565,140
+288,256
+104% +$3.92M
1
2 3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Stempoint Capital held 119 positions worth $583M, up 17% from $499M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Stempoint Capital withdrew a net $23.8M in Q4 2025, closing 42 positions and reducing 17 holdings. Its most notable exit was Wave Life Sciences, an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Twist Bioscience worth $16.4M.

  • Stempoint Capital's largest Q4 2025 buy was Twist Bioscience: 518,355 shares worth $16.4M.
  • Stempoint Capital added most to Arcellx in Q4 2025, an estimated $25.6M increase.
  • Stempoint Capital's biggest Q4 2025 reduction was Roivant Sciences, cutting an estimated $63.7M.
  • Stempoint Capital fully exited Wave Life Sciences in Q4 2025, selling an estimated $15.4M.
  • Stempoint Capital's ten largest holdings make up 46% of its $583M portfolio in Q4 2025.
  • Stempoint Capital opened 32 new positions and closed 42 in Q4 2025.
  • Stempoint Capital's portfolio value rose 17% quarter-over-quarter to $583M.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.